NCT00738673 - Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Prostate Cancer

Interventions

DRUG

degarelix

Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).

Trial Locations (15)

Urologische Praxis, Hagenow

Urologische Praxis, Bautzen

Urologische Klinik, Berlin

Urologische Praxis, Berlin

Urologische Praxis, Borken

Urologische Praxis, Cologne

Urologische Praxis, Erkrath - Hochdal

Martini Klinik, Hamburg

Urologische Praxis, Husum

Urologische Praxis, Kirchheim

Urologische Praxis, Lauenburg/Elbe

Urologische Praxis, Leipzig

Urologische Praxis, Markkleeberg

Urologische Klinik, Planegg

Wissenschaftskontor Nord, Rostock